Journals / Gülhane Tıp Dergisi / 2008 / Cilt: 50 - Sayı: 1

The effects of bevacizumab and pegaptanip sodium on in vivo angiogenesis in chick chorioallantoic membrane

Bevakizumab ve pegaptanip sodyum'un civciv koryoallantoik membrandaki in vivo anjiyogenez üzerine etkisi

Pages
19–22
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

These findings may have resulted from inadequate doses of drugs chosen or from different features of human and chick vascular endothelial growth factor isoforms, and thus, more detailed studies are needed to perform.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The effects of Bevacizumab and Pegaptanip sodium on in vivo angiogenesis in chick chorioallantoic membrane The purpose of this study was to demonstrate the anti- angiogenic efficacy of the two agents (Pegaptanip sodium and Bevacizumab), which are commonly used in the treat- ment of age-dependent macula degeneration in chick chorioallantoic membran model.
📊
Key Findings & Data:Results were evaluated at the 48th hour after application.
💡
Conclusion & Impact:These findings may have resulted from inadequate doses of drugs chosen or from different features of human and chick vascular endothelial growth factor isoforms, and thus, more detailed studies are needed to perform.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:İlaçların fizyolojik etkileri · Yumurtalar · Anjiogenezis inhibitörleri

Abstract

The effects of Bevacizumab and Pegaptanip sodium on in vivo angiogenesis in chick chorioallantoic membrane The purpose of this study was to demonstrate the anti- angiogenic efficacy of the two agents (Pegaptanip sodium and Bevacizumab), which are commonly used in the treat- ment of age-dependent macula degeneration in chick chorioallantoic membran model. Fertilized eggs obtained from Atak-S type chicken were used. The eggs were kept under appropriate heat and humidity until the fifth day on when the application would be performed. Pegaptanip sodi- um and Bevacizumab were applied to eggs at different con- centrations, and the eggs were kept under an appropriate condition until the evaluation of the results. Results were evaluated at the 48th hour after application. Although both of the two agents have affirmative effects on age-dependent macula degeneration in humans, they did not have any anti- angiogenic effects in chick chorioallantoic membran model. These findings may have resulted from inadequate doses of drugs chosen or from different features of human and chick vascular endothelial growth factor isoforms, and thus, more detailed studies are needed to perform.

Özet

Bu çalışmanın amacı, yaşa bağlı maküla dejenerasyonunun tedavisinde sıkça kullanılan iki preparatın (Pegaptanip sodyum ve Bevakizumab) anti-anjiyojenik etkinliğini civciv koryoallantoik membran modelinde göstermektir. Çalışmada, Atak-S cinsi tavuklardan alınan döllenmiş yumurtalar kullanıldı. Yumurtalar uygun nem ve sıcaklık şartları altında uygulamanın yapılacağı 5. güne kadar bekletildi. Daha sonra Pegaptanip sodyum ve Bevakizumab'ın farklı konsantrasyonları yumurtalara uygulandı ve sonuçlar değerlendirilinceye kadar uygun koşullarda saklandı. Sonuçlar, uygulama sonrası 48. saatte değerlendirildi. Her iki ilacın da insanlarda yaşa bağlı maküla dejenerasyonundaki olumlu etkilerine rağmen, civciv koryoallantoik membran modelinde anti-anjiyojenik etkileri gözlenmedi. Bu sonuçların seçilen ilaç dozlarının yetersizliğinden veya insan ve civciv damar endotelinin büyüme faktörü izoformlarının farklı özelliklerinden kaynaklanmış olabileceği düşünülmüş ve bu nedenle daha detaylı çalışmalara ihtiyaç olduğu sonucuna varılmıştır.

🔖

Cite This Article

DURUKAN, A. H., ÖZGÜRTAŞ, T., ERBİL, M. K., AYDIN, İ., MUMCUOĞLU, T., TAPAN, S., KARAGÜL, S. (2008). The effects of bevacizumab and pegaptanip sodium on in vivo angiogenesis in chick chorioallantoic membrane. Gülhane Tıp Dergisi, Cilt: 50 - Sayı: 1, 19–22. https://ajindex.com/articles/225523

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Costa C, Soares R, Schmitt F. Angiogenesis: now and then. APMIS 2004; 112: 402-412
  2. Ribatti D, Vacca A, Presta M. The discovery of angiogenic factors: a historical review. Gen Pharmacol 2002; 35: 227- 231
  3. Norrby K. In-vivo models of angiogenesis. J Cell Mol Med 2006; 10: 588-612
  4. Ng EW, Shima DT, Calias P, Cunnigham ET Jr, Guyer DR, Adamis AP. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 2006; 5: 123-132
  5. Eyetech Study Group. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degen- eration. Retina 2002; 22: 143-152
  6. Ribatti D, Vacca A, Roncali L, Dammacco F. The chick embryo chorioallantoic membrane as a model for in vivo research on angiogenesis. Int J Dev Biol 1996; 40: 1189- 1197
  7. Kaiser PK. Antivascular endothelial growth factor agents and their development: therapeutic implications in ocular disease. Am J Ophtalmol 2006; 142: 660-668
  8. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secret- ed angiogenic mitogen. Science 1989; 246: 1306-1309
  9. Houck KA, Ferrara N, Winer J, Cachianes G, Li B, Leung DW. The vascular endothelial growth factor family: iden- tification of a fourth molecular species and characteriza- tion of alternative splicing of RNA. Mol Endocrinol 1991; 5: 1806-1814
  10. Lei J, Jiang A, Pei D. Identification and characterization of a new splicing variant of vascular endothelial growth fac- tor: VEGF183. Biochim Biophys Acta 1998; 1443: 400- 406
  11. Tolentino MJ, Miller JW, Gragoudas ES, Chatzistefanou K, Ferrara N, Adamis AP. Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate. Arch Opthalmol 1996; 114: 964-970
  12. Kliffen M, Sharma HS, Mooy CM, Kerkvliet S, de Jong PT. Increased expression of angiogenic growth factors in age-related maculopathy. Br J Opthalmol 1997; 81: 154- 162
  13. Kvanta A, Algvere PV, Berglin L, Seregard S. Subfoveal fibrovascular membranes in age-related macular degener- ation express vascular endothelial growth factor. Invest Opthalmol Vis Sci 1996; 37: 1929-1934
  14. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR: VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanip for neovascular age-related macular degeneration. N Engl J Med 2004; 351: 2805-2816
  15. Michels S, Rosenfeld PJ, Puli